VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
3 hedge funds and large institutions have $1.36M invested in VALEANT PHARMACEUTICALS INTL in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
228% more capital invested
Capital invested by funds: $414K → $1.36M (+$943K)
50% more funds holding
Funds holding: 2 → 3 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Cullinan Associates
Louisville,
Kentucky
|
+$935K |
| 2 |
SIM
Sonora Investment Management
Tucson,
Arizona
|
+$6.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBI
Baxter Bros Inc
Riverside,
Connecticut
|
-$185K |
VRX Hedge Fund Activity: Q4 2017 in Review
3 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q4 2017, worth a combined $1.36M — up 228% from $414K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new VRX positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Cullinan Associates, opening a new position worth an estimated $935K. The largest seller was Baxter Bros Inc, cutting an estimated $185K.
- 3 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q4 2017, up from 2 in Q3 2017.
- Funds reported $1.36M of VALEANT PHARMACEUTICALS INTL stock for Q4 2017, up 228% quarter-over-quarter.
- 1 fund opened new VALEANT PHARMACEUTICALS INTL positions in Q4 2017 and 0 closed out, a net change of +1 holder.
- The largest VALEANT PHARMACEUTICALS INTL buyer in Q4 2017 was Cullinan Associates, an estimated $935K added.
- The largest VALEANT PHARMACEUTICALS INTL seller in Q4 2017 was Baxter Bros Inc, an estimated $185K sold.
Based on aggregated 13F filings for Q4 2017.